191 related articles for article (PubMed ID: 28778440)
1. Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.
Nielsen BR; Ratzer R; Börnsen L; von Essen MR; Christensen JR; Sellebjerg F
J Neuroimmunol; 2017 Sep; 310():17-25. PubMed ID: 28778440
[TBL] [Abstract][Full Text] [Related]
2. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
Börnsen L; Christensen JR; Ratzer R; Oturai AB; Sørensen PS; Søndergaard HB; Sellebjerg F
PLoS One; 2012; 7(11):e47578. PubMed ID: 23226199
[TBL] [Abstract][Full Text] [Related]
3. Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.
Waschbisch A; Sammet L; Schröder S; Lee DH; Barrantes-Freer A; Stadelmann C; Linker RA
Clin Exp Immunol; 2014 Aug; 177(2):404-11. PubMed ID: 24730443
[TBL] [Abstract][Full Text] [Related]
4. Altered proportions of naïve, central memory and terminally differentiated central memory subsets among CD4+ and CD8 + T cells expressing CD26 in patients with type 1 diabetes.
Matteucci E; Ghimenti M; Di Beo S; Giampietro O
J Clin Immunol; 2011 Dec; 31(6):977-84. PubMed ID: 21887518
[TBL] [Abstract][Full Text] [Related]
5. Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.
Wu Q; Wang Q; Mao G; Dowling CA; Lundy SK; Mao-Draayer Y
J Immunol; 2017 Apr; 198(8):3069-3080. PubMed ID: 28258191
[TBL] [Abstract][Full Text] [Related]
6. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.
van Langelaar J; van der Vuurst de Vries RM; Janssen M; Wierenga-Wolf AF; Spilt IM; Siepman TA; Dankers W; Verjans GMGM; de Vries HE; Lubberts E; Hintzen RQ; van Luijn MM
Brain; 2018 May; 141(5):1334-1349. PubMed ID: 29659729
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis.
Pender MP; Csurhes PA; Pfluger CM; Burrows SR
Mult Scler; 2014 Dec; 20(14):1825-32. PubMed ID: 24842963
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.
Dallari S; Franciotta D; Carluccio S; Signorini L; Gastaldi M; Colombo E; Bergamaschi R; Elia F; Villani S; Ferrante P; Delbue S
J Neuroimmunol; 2015 Oct; 287():76-9. PubMed ID: 26439965
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.
Teniente-Serra A; Grau-López L; Mansilla MJ; Fernández-Sanmartín M; Ester Condins A; Ramo-Tello C; Martínez-Cáceres E
Autoimmunity; 2016 Jun; 49(4):219-28. PubMed ID: 26829210
[TBL] [Abstract][Full Text] [Related]
11. A Preliminary Comparative Assessment of the Role of CD8+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis.
Brenu EW; Broadley S; Nguyen T; Johnston S; Ramos S; Staines D; Marshall-Gradisnik S
J Immunol Res; 2016; 2016():9064529. PubMed ID: 26881265
[TBL] [Abstract][Full Text] [Related]
12. Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls.
Haegele KF; Stueckle CA; Malin JP; Sindern E
J Neuroimmunol; 2007 Feb; 183(1-2):168-74. PubMed ID: 17084910
[TBL] [Abstract][Full Text] [Related]
13. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.
Jilek S; Mathias A; Canales M; Lysandropoulos A; Pantaleo G; Schluep M; Du Pasquier RA
Mult Scler; 2014 Jun; 20(7):837-42. PubMed ID: 24258149
[TBL] [Abstract][Full Text] [Related]
15. CD8+ T cell activation correlates with disease activity in clinically isolated syndromes and is regulated by interferon-beta treatment.
Jensen J; Langkilde AR; Frederiksen JL; Sellebjerg F
J Neuroimmunol; 2006 Oct; 179(1-2):163-72. PubMed ID: 16919783
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis.
Ghadiri M; Rezk A; Li R; Evans A; Giacomini PS; Barnett MH; Antel J; Bar-Or A
Sci Rep; 2020 Jan; 10(1):356. PubMed ID: 31941953
[TBL] [Abstract][Full Text] [Related]
17. Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis.
Cobo-Calvo Á; Figueras A; Bau L; Matas E; Mañé Martínez MA; León I; Majòs C; Romero-Pinel L; Martínez-Yélamos S
Clin Immunol; 2016 Oct; 171():18-24. PubMed ID: 27496090
[TBL] [Abstract][Full Text] [Related]
18. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell.
Karaszewski JW; Reder AT; Anlar B; Kim WC; Arnason BG
Ann Neurol; 1991 Jul; 30(1):42-7. PubMed ID: 1656847
[TBL] [Abstract][Full Text] [Related]
19. [Memory T cell subsets in peripheral blood of patients with multiple sclerosis].
Liu GZ; Gao XG
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2750-2. PubMed ID: 18167264
[TBL] [Abstract][Full Text] [Related]
20. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
